At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

Discover key insights from Arvinas, Inc.'s Q2 2025 earnings call, including CEO transition, clinical milestones, Pfizer partnership updates, and ...

BridgeBio Pharma Inc (BBIO) reports a remarkable 100% growth in U.S. net sales and outlines future opportunities amidst ...

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Snap SNAP reported second-quarter revenue of $1.3 billion, up 9% year over year, largely due to strength in European markets.